Search

Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.

• FAQ
• Written

My name is Mark Baxter and from an early age I was diagnosed with a deteriorating retinal eye condition called retinitis pigmentosa or RP for short, which will slowly lead to blindness.

• Case study - community
• Written

Organising your own fundraising is great fun and a brilliant way to involve your friends, family and local community.

In April 2022 we joined with another seven leading sight loss organisations to make a public commitment to increasing the number of blind and partially sighted people employed within our sector, including at senior management level.

• News

Join Colin & Linda McArthur for their annual Isle of Wight walk in support of Retina UK. Last year's event raised a record-breaking £6,000+!

• Walks & Treks
• Isle of Wight

Come along to our Open Day at our headquarters and hear all about our upcoming 50th anniversary and our vital work.

• Fundraising Events
• United Kingdom

The following projects were being funded by Retina UK and have recently come to an end.

Our sight loss survey highlighted that you have a real appetite to get involved in representing the inherited sight loss community through activities like focus groups, surveys and research projects via the Retina UK Lived Experience Panel.

Our community is informed and knowledgeable about current research projects into the cause(s) of and treatments for these conditions.

Growth factors are substances that promote the health and function of cells and tissues in the body.